Gilead’s $7. 8 B Move Boosts Arcellx’s Stock
Arcellx’s share price has jumped sharply after Gilead Sciences announced a $7. 8 billion investment in the company’s partner drug, targeting a specific cancer type. The deal signals strong confidence from a major biotech player and lifts expectations for the drug’s future success. The partnership c